Involvement of the glutamine RF-amide peptide and its cognate receptor GPR103 in prostate cancer

Mohamed Ab Kawan, Ioannis Kyrou, Manjunath Ramanjaneya, Kevin Williams, Jeyarooban Jeyaneethi, Harpal S. Randeva, Emmanouil Karteris

Research output: Contribution to journalArticle

Abstract

Glutamine RF-amide peptide (QRFP) belongs to the RFamide neuropeptide family, which is involved in a wide spectrum of biological activities, ranging from food intake and cardiovascular functioning to analgesia, aldosterone secretion, locomotor activity and reproduction. Recently, QRFP has been demonstrated to exert its effects by activating the G protein-coupled receptor GPR103. QRFP is expressed in the brain and peripherally in the adipose tissue, bladder, colon, testis, parathyroid and thyroid gland, as well as in the prostate gland. Following lung cancer, prostate cancer constitutes the second most frequently diagnosed cancer among men, whilst obesity appears to be a contributing factor for aggressive prostate cancer. In the present study, we sought to investigate the role of QRFP in prostate cancer, using two androgen-independent human prostate cancer cell lines (PC3 and DU145) as in vitro experimental models and clinical human prostate cancer samples. The expression of both QRFP and GPR103 at the gene and protein level was higher in human prostate cancer tissue samples compared to control and benign prostatic hyperplasia (BHP) samples. Furthermore, in both prostate cancer cell lines used in the present study, QRFP treatment induced the phosphorylation of ERK1/2, p38, JNK and Akt. In addition, QRFP increased cell migration and invasion in these in vitro models, with the increased expression of MMP2. Furthermore, we demonstrated that the pleiotropic adipokine, leptin, increased the expression of QRFP and GPR103 in PC3 prostate cancer cells via a PI3K- and MAPK-dependent mechanism, indicating a novel potential link between adiposity and prostate cancer. Our findings expand the existing evidence and provide novel insight into the implication of QRFP in prostate cancer.

LanguageEnglish
Pages1140-1150
Number of pages11
JournalOncology Reports
Volume41
Issue number2
Early online date27 Nov 2018
DOIs
Publication statusPublished - 1 Feb 2019

Fingerprint

Glutamine
Amides
Prostatic Neoplasms
Peptides
Cell Line
Adipokines
Parathyroid Glands
Adiposity
Prostatic Hyperplasia
Locomotion
G-Protein-Coupled Receptors
Leptin
Neuropeptides
Aldosterone
Phosphatidylinositol 3-Kinases
Analgesia
Androgens
Cell Movement
Reproduction
Adipose Tissue

Bibliographical note

© Kawan et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

Keywords

  • G protein-coupled receptor
  • G protein-coupled receptor 103
  • Glutamine RF-amide peptide
  • Prostate cancer

Cite this

Kawan, M. A., Kyrou, I., Ramanjaneya, M., Williams, K., Jeyaneethi, J., Randeva, H. S., & Karteris, E. (2019). Involvement of the glutamine RF-amide peptide and its cognate receptor GPR103 in prostate cancer. Oncology Reports, 41(2), 1140-1150. https://doi.org/10.3892/or.2018.6893
Kawan, Mohamed Ab ; Kyrou, Ioannis ; Ramanjaneya, Manjunath ; Williams, Kevin ; Jeyaneethi, Jeyarooban ; Randeva, Harpal S. ; Karteris, Emmanouil. / Involvement of the glutamine RF-amide peptide and its cognate receptor GPR103 in prostate cancer. In: Oncology Reports. 2019 ; Vol. 41, No. 2. pp. 1140-1150.
@article{97fb456073ee4ee68bfc142413198459,
title = "Involvement of the glutamine RF-amide peptide and its cognate receptor GPR103 in prostate cancer",
abstract = "Glutamine RF-amide peptide (QRFP) belongs to the RFamide neuropeptide family, which is involved in a wide spectrum of biological activities, ranging from food intake and cardiovascular functioning to analgesia, aldosterone secretion, locomotor activity and reproduction. Recently, QRFP has been demonstrated to exert its effects by activating the G protein-coupled receptor GPR103. QRFP is expressed in the brain and peripherally in the adipose tissue, bladder, colon, testis, parathyroid and thyroid gland, as well as in the prostate gland. Following lung cancer, prostate cancer constitutes the second most frequently diagnosed cancer among men, whilst obesity appears to be a contributing factor for aggressive prostate cancer. In the present study, we sought to investigate the role of QRFP in prostate cancer, using two androgen-independent human prostate cancer cell lines (PC3 and DU145) as in vitro experimental models and clinical human prostate cancer samples. The expression of both QRFP and GPR103 at the gene and protein level was higher in human prostate cancer tissue samples compared to control and benign prostatic hyperplasia (BHP) samples. Furthermore, in both prostate cancer cell lines used in the present study, QRFP treatment induced the phosphorylation of ERK1/2, p38, JNK and Akt. In addition, QRFP increased cell migration and invasion in these in vitro models, with the increased expression of MMP2. Furthermore, we demonstrated that the pleiotropic adipokine, leptin, increased the expression of QRFP and GPR103 in PC3 prostate cancer cells via a PI3K- and MAPK-dependent mechanism, indicating a novel potential link between adiposity and prostate cancer. Our findings expand the existing evidence and provide novel insight into the implication of QRFP in prostate cancer.",
keywords = "G protein-coupled receptor, G protein-coupled receptor 103, Glutamine RF-amide peptide, Prostate cancer",
author = "Kawan, {Mohamed Ab} and Ioannis Kyrou and Manjunath Ramanjaneya and Kevin Williams and Jeyarooban Jeyaneethi and Randeva, {Harpal S.} and Emmanouil Karteris",
note = "{\circledC} Kawan et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].",
year = "2019",
month = "2",
day = "1",
doi = "10.3892/or.2018.6893",
language = "English",
volume = "41",
pages = "1140--1150",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "2",

}

Kawan, MA, Kyrou, I, Ramanjaneya, M, Williams, K, Jeyaneethi, J, Randeva, HS & Karteris, E 2019, 'Involvement of the glutamine RF-amide peptide and its cognate receptor GPR103 in prostate cancer' Oncology Reports, vol. 41, no. 2, pp. 1140-1150. https://doi.org/10.3892/or.2018.6893

Involvement of the glutamine RF-amide peptide and its cognate receptor GPR103 in prostate cancer. / Kawan, Mohamed Ab; Kyrou, Ioannis; Ramanjaneya, Manjunath; Williams, Kevin; Jeyaneethi, Jeyarooban; Randeva, Harpal S.; Karteris, Emmanouil.

In: Oncology Reports, Vol. 41, No. 2, 01.02.2019, p. 1140-1150.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Involvement of the glutamine RF-amide peptide and its cognate receptor GPR103 in prostate cancer

AU - Kawan, Mohamed Ab

AU - Kyrou, Ioannis

AU - Ramanjaneya, Manjunath

AU - Williams, Kevin

AU - Jeyaneethi, Jeyarooban

AU - Randeva, Harpal S.

AU - Karteris, Emmanouil

N1 - © Kawan et al. This is an open access article distributed under the terms of Creative Commons Attribution License [CC BY 4.0].

PY - 2019/2/1

Y1 - 2019/2/1

N2 - Glutamine RF-amide peptide (QRFP) belongs to the RFamide neuropeptide family, which is involved in a wide spectrum of biological activities, ranging from food intake and cardiovascular functioning to analgesia, aldosterone secretion, locomotor activity and reproduction. Recently, QRFP has been demonstrated to exert its effects by activating the G protein-coupled receptor GPR103. QRFP is expressed in the brain and peripherally in the adipose tissue, bladder, colon, testis, parathyroid and thyroid gland, as well as in the prostate gland. Following lung cancer, prostate cancer constitutes the second most frequently diagnosed cancer among men, whilst obesity appears to be a contributing factor for aggressive prostate cancer. In the present study, we sought to investigate the role of QRFP in prostate cancer, using two androgen-independent human prostate cancer cell lines (PC3 and DU145) as in vitro experimental models and clinical human prostate cancer samples. The expression of both QRFP and GPR103 at the gene and protein level was higher in human prostate cancer tissue samples compared to control and benign prostatic hyperplasia (BHP) samples. Furthermore, in both prostate cancer cell lines used in the present study, QRFP treatment induced the phosphorylation of ERK1/2, p38, JNK and Akt. In addition, QRFP increased cell migration and invasion in these in vitro models, with the increased expression of MMP2. Furthermore, we demonstrated that the pleiotropic adipokine, leptin, increased the expression of QRFP and GPR103 in PC3 prostate cancer cells via a PI3K- and MAPK-dependent mechanism, indicating a novel potential link between adiposity and prostate cancer. Our findings expand the existing evidence and provide novel insight into the implication of QRFP in prostate cancer.

AB - Glutamine RF-amide peptide (QRFP) belongs to the RFamide neuropeptide family, which is involved in a wide spectrum of biological activities, ranging from food intake and cardiovascular functioning to analgesia, aldosterone secretion, locomotor activity and reproduction. Recently, QRFP has been demonstrated to exert its effects by activating the G protein-coupled receptor GPR103. QRFP is expressed in the brain and peripherally in the adipose tissue, bladder, colon, testis, parathyroid and thyroid gland, as well as in the prostate gland. Following lung cancer, prostate cancer constitutes the second most frequently diagnosed cancer among men, whilst obesity appears to be a contributing factor for aggressive prostate cancer. In the present study, we sought to investigate the role of QRFP in prostate cancer, using two androgen-independent human prostate cancer cell lines (PC3 and DU145) as in vitro experimental models and clinical human prostate cancer samples. The expression of both QRFP and GPR103 at the gene and protein level was higher in human prostate cancer tissue samples compared to control and benign prostatic hyperplasia (BHP) samples. Furthermore, in both prostate cancer cell lines used in the present study, QRFP treatment induced the phosphorylation of ERK1/2, p38, JNK and Akt. In addition, QRFP increased cell migration and invasion in these in vitro models, with the increased expression of MMP2. Furthermore, we demonstrated that the pleiotropic adipokine, leptin, increased the expression of QRFP and GPR103 in PC3 prostate cancer cells via a PI3K- and MAPK-dependent mechanism, indicating a novel potential link between adiposity and prostate cancer. Our findings expand the existing evidence and provide novel insight into the implication of QRFP in prostate cancer.

KW - G protein-coupled receptor

KW - G protein-coupled receptor 103

KW - Glutamine RF-amide peptide

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85058873386&partnerID=8YFLogxK

UR - https://www.spandidos-publications.com/10.3892/or.2018.6893

U2 - 10.3892/or.2018.6893

DO - 10.3892/or.2018.6893

M3 - Article

VL - 41

SP - 1140

EP - 1150

JO - Oncology Reports

T2 - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 2

ER -